BE1003663A3 - Nouveaux sels antiviraux, compositions pharmaceutiques les contenant et procede pour les preparer. - Google Patents
Nouveaux sels antiviraux, compositions pharmaceutiques les contenant et procede pour les preparer. Download PDFInfo
- Publication number
- BE1003663A3 BE1003663A3 BE8900253A BE8900253A BE1003663A3 BE 1003663 A3 BE1003663 A3 BE 1003663A3 BE 8900253 A BE8900253 A BE 8900253A BE 8900253 A BE8900253 A BE 8900253A BE 1003663 A3 BE1003663 A3 BE 1003663A3
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- acid
- general formula
- salts
- mixture
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 23
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 10
- 150000001413 amino acids Chemical class 0.000 claims abstract description 10
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 3
- -1 alkali metal cation Chemical class 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 3
- 125000003277 amino group Chemical group 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 28
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 25
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 23
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 19
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 14
- 239000004472 Lysine Substances 0.000 claims description 13
- 235000001014 amino acid Nutrition 0.000 claims description 9
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 9
- 235000019766 L-Lysine Nutrition 0.000 claims description 8
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 8
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000000194 fatty acid Substances 0.000 description 16
- 235000014113 dietary fatty acids Nutrition 0.000 description 15
- 229930195729 fatty acid Natural products 0.000 description 15
- 150000004665 fatty acids Chemical class 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000000354 decomposition reaction Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 229960003646 lysine Drugs 0.000 description 9
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 229930003427 Vitamin E Natural products 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- 229960002885 histidine Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 108010062580 Concanavalin A Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 239000011833 salt mixture Substances 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- HZRUTVAFDWTKGD-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;hydrate Chemical compound O.NCCCC[C@H](N)C(O)=O HZRUTVAFDWTKGD-JEDNCBNOSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- VWVRASTUFJRTHW-UHFFFAOYSA-N 2-[3-(azetidin-3-yloxy)-4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(OC2CNC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VWVRASTUFJRTHW-UHFFFAOYSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 206010061978 Genital lesion Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010021460 Immunodeficiency syndromes Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019516 cod Nutrition 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- VVDGWALACJEJKG-UHFFFAOYSA-N iodamide Chemical compound CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VVDGWALACJEJKG-UHFFFAOYSA-N 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU881131A HU199775B (en) | 1988-03-09 | 1988-03-09 | Process for production of formed by fatty acids salts of amin acids and medical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE1003663A3 true BE1003663A3 (fr) | 1992-05-19 |
Family
ID=10952971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE8900253A BE1003663A3 (fr) | 1988-03-09 | 1989-03-09 | Nouveaux sels antiviraux, compositions pharmaceutiques les contenant et procede pour les preparer. |
Country Status (16)
| Country | Link |
|---|---|
| JP (1) | JP2751068B2 (de) |
| KR (1) | KR0140993B1 (de) |
| AT (1) | AT398073B (de) |
| BE (1) | BE1003663A3 (de) |
| CA (1) | CA1339147C (de) |
| CH (1) | CH678851A5 (de) |
| DE (1) | DE3907688C2 (de) |
| ES (1) | ES2010439A6 (de) |
| FI (1) | FI93949C (de) |
| FR (1) | FR2628419B1 (de) |
| GB (1) | GB2216522B (de) |
| HU (1) | HU199775B (de) |
| IT (1) | IT1229563B (de) |
| LU (1) | LU87470A1 (de) |
| NL (1) | NL8900573A (de) |
| SE (1) | SE508603C2 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04279523A (ja) * | 1991-01-11 | 1992-10-05 | Nisshin Flour Milling Co Ltd | 免疫賦活油脂加工品 |
| WO1993000084A1 (en) * | 1991-06-24 | 1993-01-07 | Adelaide Children's Hospital | Methods and compositions for treating malaria and other diseases |
| US5767156A (en) * | 1993-10-06 | 1998-06-16 | Peptide Technology Limited | Polyunsaturated fatty acids and uses thereof |
| NL9401743A (nl) * | 1994-10-20 | 1996-06-03 | Prospa Bv | Zouten van aminoalcoholen en farmaceutische formuleringen die deze bevatten. |
| AUPM906594A0 (en) * | 1994-10-26 | 1994-11-17 | Peptide Technology Limited | Synthetic polyunsaturated fatty acid analogues |
| US5639858A (en) * | 1995-03-22 | 1997-06-17 | Tularik, Inc. | Human signal transducer and binding assays |
| HU227588B1 (hu) * | 2004-12-03 | 2011-09-28 | Sinnex Mueszaki Fejlesztoe Es Tanacsado Kft | Többszörösen telítetlen zsírsavak észtereit tartalmazó vírusellenes és immunstimuláns gyógyászati készítmény |
| BRPI0620811A2 (pt) | 2005-12-30 | 2011-11-22 | Revance Therapeutics Inc | heterÈmeros de arginina para administração tópica |
| BR112017013319B1 (pt) * | 2014-12-23 | 2021-11-30 | Evonik Operations Gmbh | Processo para aumentar a estabilidade de uma composição que compreende ácidos graxos ômega 3 poli-insaturados, composição e uso da mesma |
| EP3248467A1 (de) * | 2016-05-25 | 2017-11-29 | Evonik Technochemie GmbH | Verfahren zur herstellung einer zusammensetzung enthaltend omega-3-fettsäure-l-lysin-salze |
| CN111032032B (zh) * | 2017-08-15 | 2024-01-02 | 赢创运营有限公司 | 具有高活性成分含量的ω-3脂肪酸氨基酸盐的片剂 |
| EP4097202A4 (de) * | 2020-01-30 | 2024-01-03 | Silicycle Inc. | Verfahren zur herstellung von festen neutralen aminosäuresalzen mehrfach ungesättigter fettsäuren |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2305553A1 (de) * | 1972-02-04 | 1973-08-09 | Univ Minnesota | Arzneimittel zur behandlung von virusinfektionen |
| US4513008A (en) * | 1982-07-30 | 1985-04-23 | The Vinoxen Company, Inc. | Virucidal compositions and therapy |
| US4537772A (en) * | 1984-05-02 | 1985-08-27 | Merck & Co., Inc. | Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines |
| GB2181647A (en) * | 1985-10-01 | 1987-04-29 | Jean Morelle | Compositions based on lysine and arginine salts |
| JPS63230632A (ja) * | 1987-03-20 | 1988-09-27 | Nippon Oil & Fats Co Ltd | リポキシゲナ−ゼ代謝刺激剤 |
| DE3726299A1 (de) * | 1987-06-26 | 1989-02-23 | Dietl Hans | Fettemulsion zur intravenoesen anwendung |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8327911D0 (en) * | 1983-10-19 | 1983-11-23 | Ciba Geigy Ag | Salts as corrosion inhibitors |
-
1988
- 1988-03-09 HU HU881131A patent/HU199775B/hu not_active IP Right Cessation
-
1989
- 1989-03-06 CH CH820/89A patent/CH678851A5/de not_active IP Right Cessation
- 1989-03-07 AT AT0050989A patent/AT398073B/de not_active IP Right Cessation
- 1989-03-09 FR FR898903084A patent/FR2628419B1/fr not_active Expired - Fee Related
- 1989-03-09 FI FI891144A patent/FI93949C/fi not_active IP Right Cessation
- 1989-03-09 DE DE3907688A patent/DE3907688C2/de not_active Expired - Fee Related
- 1989-03-09 CA CA000593269A patent/CA1339147C/en not_active Expired - Fee Related
- 1989-03-09 IT IT8919705A patent/IT1229563B/it active
- 1989-03-09 KR KR1019890002919A patent/KR0140993B1/ko not_active Expired - Fee Related
- 1989-03-09 NL NL8900573A patent/NL8900573A/nl not_active Application Discontinuation
- 1989-03-09 GB GB8905384A patent/GB2216522B/en not_active Expired - Fee Related
- 1989-03-09 JP JP1055241A patent/JP2751068B2/ja not_active Expired - Lifetime
- 1989-03-09 SE SE8900827A patent/SE508603C2/sv not_active IP Right Cessation
- 1989-03-09 ES ES8900861A patent/ES2010439A6/es not_active Expired
- 1989-03-09 LU LU87470A patent/LU87470A1/fr unknown
- 1989-03-09 BE BE8900253A patent/BE1003663A3/fr not_active IP Right Cessation
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2305553A1 (de) * | 1972-02-04 | 1973-08-09 | Univ Minnesota | Arzneimittel zur behandlung von virusinfektionen |
| US4513008A (en) * | 1982-07-30 | 1985-04-23 | The Vinoxen Company, Inc. | Virucidal compositions and therapy |
| US4537772A (en) * | 1984-05-02 | 1985-08-27 | Merck & Co., Inc. | Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines |
| GB2181647A (en) * | 1985-10-01 | 1987-04-29 | Jean Morelle | Compositions based on lysine and arginine salts |
| JPS63230632A (ja) * | 1987-03-20 | 1988-09-27 | Nippon Oil & Fats Co Ltd | リポキシゲナ−ゼ代謝刺激剤 |
| DE3726299A1 (de) * | 1987-06-26 | 1989-02-23 | Dietl Hans | Fettemulsion zur intravenoesen anwendung |
Non-Patent Citations (1)
| Title |
|---|
| World Patent Index Latest database, accession no 88-312209, week 44, 1988, Derwent Publications & JP-A-63-230632 (27.09.88) (Nippon Oils And Fats) * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB8905384D0 (en) | 1989-04-19 |
| ES2010439A6 (es) | 1989-11-01 |
| JP2751068B2 (ja) | 1998-05-18 |
| NL8900573A (nl) | 1989-10-02 |
| SE8900827L (sv) | 1989-09-10 |
| SE508603C2 (sv) | 1998-10-19 |
| HUT49564A (en) | 1989-10-30 |
| CA1339147C (en) | 1997-07-29 |
| GB2216522B (en) | 1992-01-02 |
| DE3907688C2 (de) | 1996-09-05 |
| FI891144A0 (fi) | 1989-03-09 |
| DE3907688A1 (de) | 1989-09-21 |
| FR2628419B1 (fr) | 1992-02-14 |
| SE8900827D0 (sv) | 1989-03-09 |
| CH678851A5 (de) | 1991-11-15 |
| JPH024746A (ja) | 1990-01-09 |
| KR0140993B1 (ko) | 1998-07-01 |
| HU199775B (en) | 1990-03-28 |
| FI93949B (fi) | 1995-03-15 |
| LU87470A1 (fr) | 1990-10-02 |
| IT8919705A0 (it) | 1989-03-09 |
| ATA50989A (de) | 1994-01-15 |
| FI93949C (fi) | 1995-06-26 |
| FI891144L (fi) | 1989-09-10 |
| GB2216522A (en) | 1989-10-11 |
| AT398073B (de) | 1994-09-26 |
| KR890014451A (ko) | 1989-10-23 |
| FR2628419A1 (fr) | 1989-09-15 |
| IT1229563B (it) | 1991-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU87471A1 (fr) | Compositions pharmaceutiques antivirales et immunostimulantes et procede pour les preparer | |
| CA2024419C (fr) | Nouveaux sels de metaux bivalents de l'acide n,n-di(carboxymethyl) amino-2cyano-3carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant | |
| BE1003663A3 (fr) | Nouveaux sels antiviraux, compositions pharmaceutiques les contenant et procede pour les preparer. | |
| EP0233106A1 (de) | (-)-Benzhydrylsulfinylacetamid, Verfahren zur Herstellung und Verwendung in der Therapie | |
| EP0165919A1 (de) | (R)-Alpha-ethyl-2-oxo-1-pyrrolidinacetamid | |
| US4684482A (en) | Orally effective ion chelators | |
| EP0087378B1 (de) | Oximäther von Alkylaminoalkoholen als Heilmittelverbindungen und Verfahren zu ihrer Herstellung | |
| EP0113330B1 (de) | Acylierte Enamidverbindungen, diese enthaltende pharmazeutische Zusammensetzungen und Verwendung dieser Verbindungen | |
| US5047421A (en) | Orally effective ion chelators | |
| FR2553663A1 (fr) | Derives du 1,2-dithiolanne, leur preparation et leur utilisation comme medicaments | |
| FR2470110A1 (fr) | Derives de la decrapenylamine, leurs sels acides d'addition et composition pharmaceutique renfermant ces produits | |
| HU200987B (en) | Process for production of derivatives of gem-dihalogene-1,8-diamin-4-aza-octane and medical compositions containing them | |
| EP0813529A1 (de) | Arginnin analoge mit no- syntax inhibierenderwirkung | |
| FR2622195A1 (fr) | Nouveaux isopolypeptides, procede pour leur preparation et medicaments les contenant | |
| CH624922A5 (en) | Process for the preparation of new methylamine derivatives | |
| CH658786A5 (fr) | Medicaments qui contiennent d'alpha-(n-pyrrolyl)-acides ou de leurs sels ou esters. | |
| EP0220409A2 (de) | GEM-Dihalo und Tetrahalo-1,12-diamino-4,9-diaza-dodecane | |
| FR2459045A1 (fr) | Combinaisons antivirales comprenant une quinoxaline et une amine steriquement encombree | |
| CA2193096C (fr) | Derives de l'acide guanylique et applications comme medicaments | |
| EP0766692B1 (de) | Guanylsäure derivate und ihre verwendung als arzneimittel | |
| FR2491471A1 (fr) | Benzoxazolinones substituees, leur preparation et leur application en therapeutique | |
| CH495955A (fr) | Procédé de préparation de bases de Mannich de l'a-6-deoxy-5-oxy-tétracycline | |
| JPH07118231A (ja) | スルファモイル安息香酸誘導体 | |
| FR2488256A1 (fr) | Nouveaux derives de l'acide nitro-5-imidazolyl-ethenyl-2-(amino-2-pyrimidyl)-n-succinique, leur procede de preparation et medicaments en contenant | |
| FR2721826A1 (fr) | Utilisation de composes 2, 6-di-t-butylphenols substitues en position 4 dans le traitement et la prevention du sida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: BIOREX KFT Effective date: 20000331 |